These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 32460984)
21. Current and evolving understanding of atypical chronic myeloid leukemia. Schwartz LC; Mascarenhas J Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497 [TBL] [Abstract][Full Text] [Related]
22. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms. Gerke MB; Christodoulou I; Karantanos T Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631 [TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term? Shallis RM; Zeidan AM Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977 [TBL] [Abstract][Full Text] [Related]
24. Myelodysplastic and myeloproliferative disorders in children. Hasle H Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655 [TBL] [Abstract][Full Text] [Related]
26. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T. Talati C; Padron E Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113 [TBL] [Abstract][Full Text] [Related]
27. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278 [TBL] [Abstract][Full Text] [Related]
28. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Orazi A; Germing U Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833 [TBL] [Abstract][Full Text] [Related]
29. Relapse and cytogenetic evolution in myeloid neoplasms. Ertz-Archambault N; Kelemen K Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072 [TBL] [Abstract][Full Text] [Related]
30. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Palomo L; Ibáñez M; Abáigar M; Vázquez I; Álvarez S; Cabezón M; Tazón-Vega B; Rapado I; Fuster-Tormo F; Cervera J; Benito R; Larrayoz MJ; Cigudosa JC; Zamora L; Valcárcel D; Cedena MT; Acha P; Hernández-Sánchez JM; Fernández-Mercado M; Sanz G; Hernández-Rivas JM; Calasanz MJ; Solé F; Such E; Br J Haematol; 2020 Mar; 188(5):605-622. PubMed ID: 31621063 [TBL] [Abstract][Full Text] [Related]
31. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Bain BJ Leuk Lymphoma; 1999 Aug; 34(5-6):443-9. PubMed ID: 10492067 [TBL] [Abstract][Full Text] [Related]
32. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms. Cao YG; He Y; Zhang SD; Liu ZX; Zhai WH; Ma QL; Pang AM; Wei JL; Yang DL; Huang Y; Feng SZ; Jiang EL; Han MZ Biol Blood Marrow Transplant; 2020 Feb; 26(2):285-291. PubMed ID: 31494229 [TBL] [Abstract][Full Text] [Related]
33. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). Smith BN; Savona M; Komrokji RS Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):1-8. PubMed ID: 30555034 [TBL] [Abstract][Full Text] [Related]
34. Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative? Itzykson R; Fenaux P; Solary E Best Pract Res Clin Haematol; 2013 Dec; 26(4):387-400. PubMed ID: 24507815 [TBL] [Abstract][Full Text] [Related]
35. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice. Patnaik MM; Tefferi A Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006 [TBL] [Abstract][Full Text] [Related]
36. Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. Karantanos T; Jain T; Moliterno AR; Jones RJ; DeZern AE Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807519 [TBL] [Abstract][Full Text] [Related]
37. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373 [TBL] [Abstract][Full Text] [Related]
38. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910 [TBL] [Abstract][Full Text] [Related]
39. I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes. Gerds AT Curr Hematol Malig Rep; 2014 Dec; 9(4):400-6. PubMed ID: 25195196 [TBL] [Abstract][Full Text] [Related]
40. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]